News

The milestone payment is part of an exclusive commercial licensing agreement for Ceplene with Meda in Europe and certain Pacific Rim countries signed by the two companies in

GlycoVaxyn said that using its proprietary technology, staphylococcal surface polysaccharides will be conjugated in-vivo to conserved protein antigens from S aureus. The efficacy of this new bioconjugate vaccine

As per the agreement, BioSeek is expected to apply its proprietary BioMAP platform to advance Eisai’s multiple discovery projects in the oncology and inflammation areas. The agreement encompasses

FMC has posted a net income of $80.4m for the first quarter of 2010, compared to $70.9m, for the prior year period. Income from operations was $135.9m, compared

Both the entities said that on April 22, 2010 at joint advisory committee meeting, FDA questioned the effectiveness of niacin included in the current Acurox formulation but cited

In an oral presentation at Digestive Disease Week (DDW) in New Orleans, Gary Lichtenstein, professor of medicine and director of the inflammatory bowel disease program at the Hospital

Premier Anna Bligh said that the grant supports the continuation of an existing collaboration with Maree Smith, an expert in Opioid research in pain at the University of

The sNDA approval was based on results of a double-blind, randomised, placebo-controlled, two-arm, parallel-group study which enrolled 54 adults with EPI due to CP or pancreatectomy. The primary

ReGen Therapeutics said that in in-vitro studies Colostrinin has been shown to prevent the aggregation of beta-amyloid and reduce it’s toxicity to cells. Colostrinin has also been shown